New approaches to SCLC therapy: From the laboratory to the clinic Review
| Authors: | Poirier, J. T.; George, J.; Owonikoko, T. K.; Berns, A.; Brambilla, E.; Byers, L. A.; Carbone, D.; Chen, H. J.; Christensen, C. L.; Dive, C.; Farago, A. F.; Govindan, R.; Hann, C.; Hellmann, M. D.; Horn, L.; Johnson, J. E.; Ju, Y. S.; Kang, S.; Krasnow, M.; Lee, J.; Lee, S. H.; Lehman, J.; Lok, B.; Lovly, C.; MacPherson, D.; McFadden, D.; Minna, J.; Oser, M.; Park, K.; Park, K. S.; Pommier, Y.; Quaranta, V.; Ready, N.; Sage, J.; Scagliotti, G.; Sos, M. L.; Sutherland, K. D.; Travis, W. D.; Vakoc, C. R.; Wait, S. J.; Wistuba, I.; Wong, K. K.; Zhang, H.; Daigneault, J.; Wiens, J.; Rudin, C. M.; Oliver, T. G. |
| Review Title: | New approaches to SCLC therapy: From the laboratory to the clinic |
| Abstract: | The outcomes of patients with SCLC have not yet been substantially impacted by the revolution in precision oncology, primarily owing to a paucity of genetic alterations in actionable driver oncogenes. Nevertheless, systemic therapies that include immunotherapy are beginning to show promise in the clinic. Although, these results are encouraging, many patients do not respond to, or rapidly recur after, current regimens, necessitating alternative or complementary therapeutic strategies. In this review, we discuss ongoing investigations into the pathobiology of this recalcitrant cancer and the therapeutic vulnerabilities that are exposed by the disease state. Included within this discussion, is a snapshot of the current biomarker and clinical trial landscapes for SCLC. Finally, we identify key knowledge gaps that should be addressed to advance the field in pursuit of reduced SCLC mortality. This review largely summarizes work presented at the Third Biennial International Association for the Study of Lung Cancer SCLC Meeting. © 2020 International Association for the Study of Lung Cancer |
| Keywords: | treatment outcome; survival rate; unclassified drug; clinical feature; review; cancer recurrence; cisplatin; cancer growth; nonhuman; antineoplastic agent; mitosis; biological marker; carboplatin; ipilimumab; ticilimumab; cancer immunotherapy; metastasis; apoptosis; etoposide; tumor xenograft; risk factor; immune response; epigenetics; platinum; dna damage response; clinical effectiveness; therapy; small cell lung cancer; neuroendocrine; sclc; gene mutations; nivolumab; g2 phase cell cycle checkpoint; human; priority journal; pembrolizumab; durvalumab; atezolizumab; liquid biopsy; ascl1; rovalpituzumab tesirine; molecular fingerprinting; lurbinectedin; bms 986012; mivebresib |
| Journal Title: | Journal of Thoracic Oncology |
| Volume: | 15 |
| Issue: | 4 |
| ISSN: | 1556-0864 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2020-04-01 |
| Start Page: | 520 |
| End Page: | 540 |
| Language: | English |
| DOI: | 10.1016/j.jtho.2020.01.016 |
| PUBMED: | 32018053 |
| PROVIDER: | scopus |
| PMCID: | PMC7263769 |
| DOI/URL: | |
| Notes: | Review -- Export Date: 1 April 2020 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work